Biktarvy

Showing 5 posts of 5 posts found.

gilead-sciences

Gilead’s Biktarvy proves non-inferior to standard care for HIV in Black and African American patients

October 22, 2020
Research and Development Biktarvy, Gilead, HIV, pharma

Gilead has revealed promising new Phase 3 data reinforcing the non-inferiority of Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg) compared to …

gilead-sciences

Gilead’s Biktarvy maintains HIV suppression for 48 weeks in children and adolescents

March 7, 2019
Research and Development Biktarvy, Gilead, HIV, pharma

Gilead has lifted the curtain on new Phase 2/3 efficacy data for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 …

gilead-sciences

European Commission greenlights Gilead’s Biktarvy for HIV-1

June 25, 2018
Sales and Marketing Biktarvy, EU, Europe, European Commission, HIV, HIV-1, pharma

Good news for Gilead and HIV patients across the European Union today as the prominent pharma firm announced that its …

gilead_hq_at_stockley_park_london

Switching to Gilead’s Biktarvy proves non-inferior in HIV patients

March 6, 2018
Manufacturing and Production, Research and Development Biktarvy, Gilead, HIV, pharma

Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir …

gilead-sciences

FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit

February 8, 2018
Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma

Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.

Latest content